Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2024-10-21 | New | $65,000,000 | $65,000,000 | Equity Only | 06b | SEC link |
| 2020-12-21 | New | $47,384,999 | $47,384,999 | Equity Only | 06b | SEC link |
| 2019-05-14 | New | $25,000,002 | $25,000,002 | Equity Only | 06b | SEC link |
| 2018-01-08 | New | $21,994,682 | $21,994,682 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Samuel Agresta | Executive |
| Lon Cardon, Ph.D. | Director |
| R. Michael Carruthers | Director |
| Mike Cruse | Executive |
| Alejandro Dorenbaum, M.D. | Executive |
| Gregory Flesher | Director, Executive |
| Michael G. Grey | Director |
| Kenneth Harrison | Director |
| Dylan Hartley | Executive |
| Valerie M. Jansen | Director |
| Wendy Johnson | Executive |
| Johan Kordel, Ph.D. | Director |
| Jason Leverone | Executive |
| Isaac Manke | Director |
| Ed Mathers | Director |
| Edward T. Mathers | Director |
| Bali Muralidhar | Director |
| Niall O'donnell | Director, Executive |
| Niall O'donnell, Ph.D. | Director |
| Art Pappas | Director |
| Andrew Johm Phillips | Director |
| Nicholas Saccomano | Director, Executive |
| Stacey Seltzer | Director |
| Scott Weiner | Director |